Summary
Interpretation of next-generation sequencing data of individuals with an apparent sporadic neurodevelopmental disorder (NDD) often focusses on pathogenic variants in genes associated with NDD, assuming full clinical penetrance with limited variable expressivity. Consequently, inherited variants in genes associated with dominant disorders may be overlooked when the transmitting parent is clinically unaffected. While de novo variants explain a substantial proportion of cases with NDDs, a significant number remains undiagnosed possibly explained by coding variants associated with reduced penetrance and variable expressivity. We characterized twenty families with inherited heterozygous missense or protein-truncating variants (PTVs) in CHD3, a gene in which de novo variants cause Snijders Blok-Campeau syndrome, characterized by intellectual disability, speech delay and recognizable facial features (SNIBCPS). Notably, the majority of the inherited CHD3 variants were maternally transmitted. Computational facial and human phenotype ontology-based comparisons demonstrated that the phenotypic features of probands with inherited CHD3 variants overlap with the phenotype previously associated with de novo variants in the gene, while carrier parents are mildly or not affected, suggesting variable expressivity. Additionally, similarly reduced expression levels of CHD3 protein in cells of an affected proband and of related healthy carriers with a CHD3 PTV, suggested that compensation of expression from the wildtype allele is unlikely to be an underlying mechanism. Our results point to a significant role of inherited variation in SNIBCPS, a finding that is critical for correct variant interpretation and genetic counseling and warrants further investigation towards understanding the broader contributions of such variation to the landscape of human disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are extremely grateful to all families participating in this study. In addition, we wish to thank the members of the Cell culture facility, Department of Human Genetics, RadboudUMC, Nijmegen for culture of cell lines. This work was financially supported by the Dutch Research Council grant to TK (015.014.036 and 1160.18.320) and LELMV (015014066) and Netherlands Organization for Health Research and Development to TK (91718310) and LELMV (843002608, 846002003), by Donders Junior Researcher Grant 2019 to TK and LELMV and the Max Planck Society (JdH, DS, CF, SEF). Authors of this publication are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. The aims of this study contribute to the Solve-RD project (CG, HGB, LELMV and TK) which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779257. For families 10,13,14 and 19 sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. For family 15 exome sequencing was performed in the framework of the German project "TRANSLATE NAMSE", an initiative from the National Action League for People with Rare Diseases (Nationales Aktionsbuendnis fuer Menschen mit Seltenen Erkrankungen, NAMSE) facilitating genetic diagnostics for individuals with suggested rare diseases. Part of this research has been conducted using the UK Biobank Resource under application number 16066, with Clyde Francks as the principal applicant. Our study made use of imaging-derived phenotypes generated by an image-processing pipeline developed and run on behalf of UK Biobank.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board 'Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen' under number 2011/188. This number refers to performing diagnostic WES. Discovery of novel syndromes/description if cases from this series can be taken as such.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Supplementary Notes 1, Table S1, facial photographs (Fig. 2A and Fig. S2) and all datasets generated and analyzed during the current study are available from the corresponding author on request.
